Medical Condition News

RSS

Unique resource for families facing hereditary breast and ovarian cancer

When she was forty-two, Joi Morris learned that she has a genetic mutation on a gene known as BRCA2. This meant that her risk of getting breast cancer could be as high as 84 percent by age seventy, and that her risk for ovarian cancer was also high.

23 Feb 2010

Committee calls for strategies to curb hypertension

Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.

23 Feb 2010

Combination of MRI and mammography reduces mortality rate in high-risk women

Annual breast cancer screening with both mammography and magnetic resonance imaging (MRI) is likely to be a cost-effective way to improve life expectancy in women with an increased risk of breast cancer, according to a new study published in the March issue of Radiology.

23 Feb 2010

Pulmonx to raise new funding for global launch of Zephyr EBV and Chartis Pulmonary Assessment System

Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets.

23 Feb 2010

Acute stroke care and clinical outcomes improve substantially with stroke program

Acute stroke care and clinical outcomes have improved significantly at hospitals participating in the American Heart Association/American Stroke Association's Get With The Guidelines-Stroke program, according to a large study in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

DURECT, Nycomed amend POSIDUR Development and License Agreement

DURECT Corporation announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR™ (also known as SABER™-Bupivacaine or OPTESIA™), an investigational drug for the treatment of post-surgical pain.

23 Feb 2010

Star Scientific seeks FDA marketing approval for Ariva-BDL dissolvable tobacco lozenge

Star Scientific, Inc. announced that on Friday, February 19 the company filed an application with the Food & Drug Administration for approval to market Ariva-BDL™ as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009. This submission is the first such application to be filed with the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.

23 Feb 2010

MRI: An efficient diagnostic tool for testicular cancer

Researchers have found that non-invasive magnetic resonance imaging (MRI) is a good diagnostic tool for the evaluation and staging of testicular cancer and may improve patient care by sparing some men unnecessary surgery, according to a study in the March issue of the American Journal of Roentgenology.

23 Feb 2010

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva® (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

23 Feb 2010

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.

23 Feb 2010

Senate, FDA reports increasing concerns about controversial diabetes drug

"Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market ... ," The New York Times reports. "The internal F.D.A. reports are part of a fierce debate within the agency over what to do about Avandia, manufactured by GlaxoSmithKline."

23 Feb 2010

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target criteria of sustained and robust weight loss.

23 Feb 2010

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

A new guideline from the American Academy of Neurology recommends that the drug quinine, although effective, should be avoided for treatment of routine muscle cramps due to uncommon but serious side effects.

23 Feb 2010

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.

22 Feb 2010

UIC researchers receive federal grant to study effects of TV media on children’s health outcomes

Researchers at the University of Illinois at Chicago Institute for Health Research and Policy have received a $2.2 million federal grant to determine whether or not TV food advertising affects children's diet, physical activity and weight.

22 Feb 2010

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.

22 Feb 2010

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

22 Feb 2010

ResMed launches S9 sleep apnoea therapy platform in Europe

ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.

From ResMed Corp 22 Feb 2010

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

The National Basketball Association's (NBA) Denver Nuggets Coach George Karl announced today that he has been diagnosed with treatable neck and throat cancer. According to published media reports, Karl's physician says the coach has cancer of his right tonsil that has spread to a lymph node in his neck. The 58-year-old Karl, who is also a prostate cancer survivor, coached in the NBA's All-Star game this past weekend.

22 Feb 2010

Medical Condition News

Unique resource for families facing hereditary breast and ovarian cancer

Committee calls for strategies to curb hypertension

Combination of MRI and mammography reduces mortality rate in high-risk women

Pulmonx to raise new funding for global launch of Zephyr EBV and Chartis Pulmonary Assessment System

Acute stroke care and clinical outcomes improve substantially with stroke program

Study shows CEL-2000 vaccine blocks RA progression in mice

DURECT, Nycomed amend POSIDUR Development and License Agreement

Star Scientific seeks FDA marketing approval for Ariva-BDL dissolvable tobacco lozenge

MRI: An efficient diagnostic tool for testicular cancer

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Senate, FDA reports increasing concerns about controversial diabetes drug

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

UIC researchers receive federal grant to study effects of TV media on children’s health outcomes

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

ResMed launches S9 sleep apnoea therapy platform in Europe

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News